Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks Kiwi. Does your wife find that some symposiums are poorly attended, or is it that in her particular field there is strong interest? Could the time of year have affected the attendance, as I am not sure if most of the English go on holiday in August or July? And, of course, we are speculating that it may not have been well attended.
Yep Saud. I have a few others who have reversed today and started upwards while most of the market is still under pressure. Hopefully, we will never see the 9's again, and this begins to accelerate north.
Thinking about that MKT release posted here earlier, I still wonder if a deal is close, why they even need to find replacements for those two leaving. Just wrap this up, unless they want to make it look like they can proceed on their own if no acceptable offer comes. But really everyone knows they can't GIA, so who would they be kidding.
Yep, Duke, I have always been more concerned about a stroke than a heart attack. I was very young when the realization set in (and I was easily resigned to it and accepting of it) that we are born, live, and die - all of us. So the dying is not the big problem (other than when it happens before you have a chance to raise your kids) but a debilitating stroke where you can't do anything, have to have people take care of you, and basically have a miserable existence. Even some of these medical treatments that may extend life (at the end of life mind you when there is not much enjoyable life anyway) I abhor (for myself). Seems to me to be crazy to have needles, tubes, shoved in every orifice, my carcass split open, and butchered when a few months later there is a 99% chance I will die anyway. Now I am not saying if a person is young, and will have many more years of life ahead of them. But for me to go through all that jazz to die at say, 81 instead of at 80 1/2 and not be subjected to all that extra miserable. Sorry for the diatribe - I went off on a tangent. Market miserable today and of course that does not help our little Amarin.
Hard to tell as today’s market is a bloodbath so far for virtually everyone
Thanks for posting Agordon.
Thanks for posting Doc. Of course, it brings up the question that if they find people on say, statins, have less dementia, is that because of the statin (inflammatory effects and lowering of lipids, etc.) or is it because of the fact that these lipid markers did not fluctuate (because of the statin)?
Kiwi, would there be anything where the UK Heart might have some rule or whatever that might impede Amarin from doing so? I would think not as it is Amarin's presentation, but the venue may have some stipulation, don't know.
If Omacor is still being prescribed, sold, and reimbursed for in the UK, then absolutely I hope they did that. In the EU I believe that mixed omegas are no longer covered, at least not for CVD.
Omacor in the U.S. at least, changed its name to Lovaza. We have seen the clinical trials that show that mixed omegas are ineffective for CVD protection. Sorry to hear about your friends. Hopefully, the one who is still alive has recovered and is no longer on Omacor.
Thanks for investigating. We should hear soon enough what impact it will have with health care practitioners.
Thanks Kiwi. But I guess it is already past 6 o'clock there.
Last I saw (dated 6/15/2023) there was a little less than 16 million short interest in the stock, with a little over 9 days to cover.
I guess they are either not too scared or figure they have time to get out. Plus, it doesn't seem like investors are loading the boat
either in anticipation of a sale.
Toes Crossed. You seem to have a more direct lineage to CHLCA than I, as that is something I can’t do.
Thanks for the other info.
It started today and runs through Friday.
https://www.heartuk.org.uk/conference-2023/conference-home-page
I can't remember exactly, but there was a poster who was possibly going to try to snoop around to see if they could hear anything as they apparently live not to far from the place.
JRoon, it makes sense what you say.
TalShu, to your question #5, I don’t believe there was only one statin in Reduce-It:
https://academic.oup.com/eurheartj/article/41/Supplement_2/ehaa946.3341/6004851
Definitely interested in this potential market exclusivity but would like something more concrete than “hopefully”.
I struggle with the idea that it takes so long (at least 3 years and don’t know if that estimate included approval) when both drugs are already approved drugs.
Could, I was wondering same thing and just assumed I missed something in the Spain announcement. Any clarification appreciated.
Thanks. They need to keep em coming. Slow as molasses, but I remember something about a tortoise.
Bad prose on my part. He said that they “can’t call icosapent ethyl a generic for Vascepa”.
But they certainly can. Atovastatin is a generic for Lipitor.
I goofed when I wrote Generic Vascepa, but icosapent ethyl is a generic for Vascepa.
USAFC130, I understand how GV should not be used for the CVD indication, but I am curious as to why you say Icosapent ethyl cannot be called generic Vascepa?
Jess your 2/3 must have been weeks then. Hoping we see similar here.
Thanks for posting Duke. I was thinking about the Generics (maybe it is only one company) that are suing (I believe the lawsuit is still active and ongoing but could be wrong) Amarin for hogging API when I read this line:
"However, Vascepa’s expanded sales will severely constrain the overall supply of this API, making it difficult for other companies to launch generic versions of Vascepa. "
But I guess that might not come into play as I think the Generics are saying there were other nefarious things Amarin was doing with suppliers to shut out the Generics. Writing off of a bunch of inventory though might be something the Generics could hang their hat on saying that Amarin was buying up more inventory than they needed.
Well RBC thinks high 20’s or low 30’s:
https://seekingalpha.com/news/3984684-aurinia-pharma-could-see-high-20s-to-low-30s-a-share-in-takeover-analyst
Does that mean our heads are thicker?
Do you think that hiring those M&A lawyers means that they think they are fairly close to some kind of offer?
Rafunrafun. A long time poster here who gets us the weekly script numbers.
Thanks.
Anyone how Raf is doing? Hasn’t posted in over a month I believe.
Thanks Jess. Quite an improvement over the prior week.
Some commentary:
https://twitter.com/TomSilver39/status/1674610336522174464?s=20
Also Auphie has hired the most respected M&A attorneys:
$AUPH retained Skadden, Arps, Slate, Meagher & Flom as their M&A law firm. The link below provides their Recognition. This firm has represented one of the two companies in virtually every airline merger. Their Recognition is beyond impressive.https://t.co/axFIMqE1Au
— Chip Munn (@ChipMunn1) June 30, 2023
I'm with you Jess, but you need to restrain yourself a bit. The balloon doesn't appear to have that much helium in it, as the stock price is still well below where it was a month ago.
Well now we will see if there is any interest or if they if butchered the rollout so bad that no one is interested.
It was pretty clear that PG was not going to make it past the next AGM, and it appears he finally realized it.
Envious of another BO this morning that is not us. But it shows what could have been. Again so many BOs come early and not years after drug
approval. Lilly buying Siligon Therapeutics and it is up over 700% this morning. SGTX.
Excellent post TalShu.
I have been wondering why Iljin wanted to remove those two slugs but leave PG in place. I was thinking that the idea behind that would be that it would make a BO a little easier to accomplish with PG in place. But we are not seeing much happening.
Agree with both of you and you make a good point Capt that China can be valuable in that it could make it more appealing for a BO.
So true PD. The generic in the US is only approved for VHTG, but is gobbling up scripts for CVD, so you are correct that the same will occur in China - except quicker.
Thanks Duke, appreciate all you do for the board. Such a hodgepodge it puzzles me why or how all these coverage decisions are made at all these insurers.
I just had a situation not related to V that forced me to make a call to Medicare. I got an EOB from BCBS this past weekend and they had a $7K charge for which they denied payment. I did not recognize the charge so I called them today. They said that it looked like Medicare fraud as the charge first went there and then sent on to my secondary insurance BCBS. So I then called Medicare. The charge was for some durable medical equipment - a catheter. I told them I did not ever come within 100 feet of a catheter and so they will start an investigation. Bad thing was that Medicare actually paid out over $5K on the claim so not sure why they forwarded the entire $7K on to BCBS. I am just wondering and concerned as to how they got my Medicare card number.
To be balanced, the poor overall market has punished a lot of small bios, so Auphie is no different.
On the other hand, scripts are stalling and there seems to be no plan (at least not elucidated or witnessed) to get things moving. Profitability no where in sight.
And that could be because the EMA has said that mixed omega-3 are not effective for CVD (and I assume any reimbursement for that has been withdrawn). Unlike the FDA or our moronic doctors here who pay no attention.
https://www.tctmd.com/news/european-regulators-strike-secondary-prevention-claim-omega-3-drugs